Member Info for BaxtersSoup

And he Reinvets himself do the same!

Inanco - how to get rid!Today 19:15
Click on his / her user name
Report him / her - click on his name on a post
Reason - Disruptive
Then explain your reason
The he’ll fxxx off if enough report him as l have done.

201 is an incredibly versatile - 201 for all types of cancer 301 for Endometris, BC201 for C19 | SARS |MERS and goodness know what else!

We have some interesting developments this quarter with 201 full results, 401 financing , 301 Japan update, BC201 news and any new developments.

30p looks like a solid platform for the next move up.

There was also good support and strong buying today and feel £25 mn market cap or 45p is fair intrinsic value based on the IP de-risk and value.

AIMHO

Grace, please son’t reply to him.

He clearly need to DYOR.

Moving on up!

Just one MM at 34p left to budge.

Fair value now is between 30-40 mn mkt cap so 45 to 65p l reckon. 4D and Sng is over £200 mm! Mkt cap!

Sense l think has returned;
2 years money in the bag
201 with pharmas been-in-toe for years
301 with Jap pharma.....deal pending
BC201 - update soon
401 financing news soon
Amazing

Keeptofacts, yes all good mate, very happy indeed.

Eyeguy, l believe they have been talking with pharmas for a long time on 201 so we now wait a deal and extremely confident and very excited.

The 201 headline news was one thing, a JV / licensing deal is a game changer IMHO.

Well done allnothing. Bought 120,000 this morning at 25.9 and pleased as punch.
Yes, a pharma JV and this will certainly go crazy!

Good concise interview.... 201 works and confident with the results that they’ll get a partner for next phase based on the strength of the headlines.
Onwards and upwards!

Rob, they have two years of money.
201 will be a license or JV now and 301 will be with the Japan pharma to finance.

Happy to top up here and bought 120k at 25.9
Podcast today and glad to se AH move up to 4%.
Calm nerves required but all on track and plenty of cash!

Scouse
This will be funded by a pharma partner under license / JV:

“We now intend to progress discussions with selected contacts.”

Liked these bits:

“The response rate for VAL201 in this trial is reported as 54.5%.“

“A number of major cancer drugs have been approved on the back of response rates of around 30%. We are therefore very encouraged that we have good early data for VAL201.”

“Phase 2 study..... such a trial may also include patients with different cancers where VAL201 might provide a benefit.”

And the best bit...... 201 deal:

“We now intend to progress discussions with selected contacts.”

This is certainly a possibility now, but where would investors realistically sell?

I’d probably let mine go at 40p

I thought JB would have been good for Amigo, but at least that chapter is now closed and good to get an update regarding claims and lending to resume Q4 so l think a re-rate is now on the cards up to 20p to start with and then back to one year highs in the 70’s.

Xcoder, quite!
Yes good news yesterday.
Industry standard 30% (l believe someone said)
Last 201 trial was 35-40%
Yesterday we received 55%
Now talking to pharma’s who have followed 201 progress
2 years of money in the bank to pay costs (no fund raising)
8@D

Thanks Grace and l think the podcast on BRR will be nerve calming.

In fact with BRR, Hargreaves increasing his holding and the SP consolidating today, l can’t see any reason for the SP will not to go back in to the 30’s tomorrow.